Clinical Trial Update: Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment [Phase 4]

View source ↗

Summary

Phase 4 open-label trial evaluating alfilbercept for fibrovascular pigment epithelial detachment has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrovascular Pigment Epithelial Detachment

Drugs mentioned

• Alfilbercept

Snippet

Sponsor: Vitreous -Retina- Macula Consultants of New York | Conditions: Fibrovascular Pigment Epithelial Detachment | Phase 4 | Status: WITHDRAWN